Article Archive for November 2009
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company that focuses on in-licensing, developing and bringing to market treatments for psychological and neurological disorders, has announced that the US Food and Drug Administration (FDA) had …
Simulations Plus, Inc (NASDAQ:SLP) has announced that they have released the new version of GastroPlus state of the art software which is being used by many pharmaceutical research scientists for simulation of oral absorption, intravenous …
Healthways, Inc. (NASDAQ:HWAY) and Physicians Health Choice together have announced an agreement to provide the Healthways SilverSneakers Fitness Program to eligible Physicians Health Choice plan members in Texas, Florida, Arkansas and New Mexico that will …
Whether you believe the economy is going to substantially improve over the next year, stay about the same, or get worse, you can find surveys that back up your point of view. Economic …
On 8 June 2009, Dyax Corp. (NASDAQ:DYAX), a clinical stage biopharmaceutical company that discovers, develops and commercializes biotherapeutics for inflammatory and oncology diseases, announced that it had obtained from the US Food and Drug Administration …
Santarus, Inc. (NASDAQ:SNTS) expects the FDA to decide by December 4, 2009 regarding its NDA for ZEGERID tablet product. A NDA (New Drug Application) for DM-1796 is also expected to be filed with the FDA the …
Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation (NASDAQ:CYTR). Shares of the company finished trading during 11/20/09 at $1.14 per share.
The FDA is anticipated to decide on 11/26/09 for Vibativ (telavancin) as a once-daily injectable antibiotic for the treatment of hospital-acquired pneumonia (HAP). This triggers a milestone payment of $10M from THRX’s partner, Astellas Pharma (ALPMF.PK). …
